A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.

Cancer Medicine
Patrick Wayne CobbLee S Schwartzberg

Abstract

Eflapegrastim (Rolontis® ) is a novel, long-acting hematopoietic growth factor consisting of a recombinant human granulocyte-colony stimulating factor (rhG-CSF) analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. We report results from a second pivotal, randomized, open-label, Phase 3 study comparing the efficacy and safety of eflapegrastim to pegfilgrastim for reducing the risk of chemotherapy-induced neutropenia. Patients with Stage I to IIIA early-stage breast cancer (ESBC) were randomized 1:1 to fixed-dose eflapegrastim 13.2 mg (3.6 mg G-CSF) or pegfilgrastim (6 mg G-CSF) administered one day after standard docetaxel/cyclophosphamide (TC) therapy for four cycles. The primary objective was to demonstrate noninferiority (NI) of eflapegrastim compared to pegfilgrastim in mean duration of severe neutropenia (DSN; Grade 4) in Cycle 1. A total of 237 eligible patients were randomized 1:1 to receive either eflapegrastim (n = 118) or pegfilgrastim (n = 119). Cycle 1 severe neutropenia was observed in 20.3% (n = 24) of patients receiving eflapegrastim and 23.5% (n = 28) receiving pegfilgrastim. The DSN of eflapegrastim in Cycle 1 was noninferior to pegfilgrastim with a mean difference of -0.074 days...Continue Reading

References

Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M D GreenUNKNOWN International Pegfilgrastim 749 Study Group
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanJeffrey Crawford
Sep 24, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanRichard I Fisher
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen E JonesLina Asmar
May 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hyman B MussMatti Aapro
Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicole M KudererGary H Lyman
Dec 18, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D WeyckerG Oster
Jan 1, 2008·The Oncologist·Lodovico BalducciWilliam B Ershler
Mar 6, 2008·Journal of the National Comprehensive Cancer Network : JNCCN·Jeffrey CrawfordGary H Lyman
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JonesMichael A Savin
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanJeffrey Crawford
Apr 22, 2011·Critical Reviews in Oncology/hematology·Arlene ChanTed Vandenberg
Sep 15, 2012·Experimental and Therapeutic Medicine·M Blane SchillingRobert G Deeter
Jan 30, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Kwang-Hee ShinKyung-Sang Yu
Jan 13, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Yoshimasa KosakaKazuo Tamura
May 23, 2015·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Tara ArvedsonBing-Bing Yang
Sep 25, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·David C DaleGary H Lyman
Nov 18, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Jeffrey J KirshnerPhuong Khanh Morrow
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanRichard L Schilsky

❮ Previous
Next ❯

Citations

Jun 12, 2021·Expert Review of Anticancer Therapy·Michelle ShayneGary H Lyman

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02953340
NCT02643420

Software Mentioned

Hasal

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.